Maryam Firdous, Muhammad Farooq Umer, Suriyakala Perumal Chandran
{"title":"Optical coherence tomography findings in beta-thalassemia major: a systematic review and Meta-analysis.","authors":"Maryam Firdous, Muhammad Farooq Umer, Suriyakala Perumal Chandran","doi":"10.18240/ijo.2025.06.19","DOIUrl":null,"url":null,"abstract":"<p><strong>Aim: </strong>To describe the optical coherence tomography (OCT) findings of the retinal nerve fiber layer thickness (RNFLT) and choroidal thickness (CT) in beta-thalassemia major.</p><p><strong>Methods: </strong>A systematic search was conducted on PubMed, Cochrane, and Embase using a combination of specific key words. The records found were screened in two phases (title/abstract, and full-text screening). All the original observational cross-sectional studies conducted on beta-thalassemia major cases and controls reporting the RNFLT and CT were included. The Meta-analysis was run for comparing the OCT measurements between beta-thalassemia cases and controls including pooled effect size, confidence intervals (CI), quality assessment, and publication bias. The measurements included were RNFLT (average, and in various quadrants), and CT.</p><p><strong>Results: </strong>A total of 10 studies were included in this Meta-analysis including a total of 684 individuals, 362 cases and 322 controls. The RNFLT and CT showed a significant reduction in the values of beta-thalassemia cases as compared to controls. The heterogeneity among the included studies was found to be 92.65% for the average RNFLT and 30.13% for the CT making it obvious to use random effects model for analyzing the RNFLT values while fixed effects model for the CT. The Egger's test showed significant publication bias among all the parameters except for nasal RNFLT (<i>P</i>=0.507), and CT (<i>P</i>=0.281). The estimated average effect size for the average RNFLT was 1.04 (95%CI: 0.35 to 1.72, <i>Z</i>=2.961, <i>P</i>=0.003) and for CT was 0.74 (95%CI: 0.51 to 0.96, <i>Z</i>=6.523, <i>P</i><0.001).</p><p><strong>Conclusion: </strong>This Meta-analysis concludes that the RNFLT and CT are significantly thinner in beta-thalassemia cases in comparison to healthy individuals. Therefore, the RNFLT and CT must be evaluated in routine clinical practice in order to avoid irreversible vision loss particularly in beta-thalassemia individuals.</p>","PeriodicalId":14312,"journal":{"name":"International journal of ophthalmology","volume":"18 6","pages":"1113-1122"},"PeriodicalIF":1.9000,"publicationDate":"2025-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12120446/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International journal of ophthalmology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.18240/ijo.2025.06.19","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Aim: To describe the optical coherence tomography (OCT) findings of the retinal nerve fiber layer thickness (RNFLT) and choroidal thickness (CT) in beta-thalassemia major.
Methods: A systematic search was conducted on PubMed, Cochrane, and Embase using a combination of specific key words. The records found were screened in two phases (title/abstract, and full-text screening). All the original observational cross-sectional studies conducted on beta-thalassemia major cases and controls reporting the RNFLT and CT were included. The Meta-analysis was run for comparing the OCT measurements between beta-thalassemia cases and controls including pooled effect size, confidence intervals (CI), quality assessment, and publication bias. The measurements included were RNFLT (average, and in various quadrants), and CT.
Results: A total of 10 studies were included in this Meta-analysis including a total of 684 individuals, 362 cases and 322 controls. The RNFLT and CT showed a significant reduction in the values of beta-thalassemia cases as compared to controls. The heterogeneity among the included studies was found to be 92.65% for the average RNFLT and 30.13% for the CT making it obvious to use random effects model for analyzing the RNFLT values while fixed effects model for the CT. The Egger's test showed significant publication bias among all the parameters except for nasal RNFLT (P=0.507), and CT (P=0.281). The estimated average effect size for the average RNFLT was 1.04 (95%CI: 0.35 to 1.72, Z=2.961, P=0.003) and for CT was 0.74 (95%CI: 0.51 to 0.96, Z=6.523, P<0.001).
Conclusion: This Meta-analysis concludes that the RNFLT and CT are significantly thinner in beta-thalassemia cases in comparison to healthy individuals. Therefore, the RNFLT and CT must be evaluated in routine clinical practice in order to avoid irreversible vision loss particularly in beta-thalassemia individuals.
期刊介绍：
· International Journal of Ophthalmology-IJO (English edition) is a global ophthalmological scientific publication
and a peer-reviewed open access periodical (ISSN 2222-3959 print, ISSN 2227-4898 online).
This journal is sponsored by Chinese Medical Association Xi’an Branch and obtains guidance and support from
WHO and ICO (International Council of Ophthalmology). It has been indexed in SCIE, PubMed,
PubMed-Central, Chemical Abstracts, Scopus, EMBASE , and DOAJ. IJO JCR IF in 2017 is 1.166.
IJO was established in 2008, with editorial office in Xi’an, China. It is a monthly publication. General Scientific
Advisors include Prof. Hugh Taylor (President of ICO); Prof.Bruce Spivey (Immediate Past President of ICO);
Prof.Mark Tso (Ex-Vice President of ICO) and Prof.Daiming Fan (Academician and Vice President,
Chinese Academy of Engineering.
International Scientific Advisors include Prof. Serge Resnikoff (WHO Senior Speciatist for Prevention of
blindness), Prof. Chi-Chao Chan (National Eye Institute, USA) and Prof. Richard L Abbott (Ex-President of
AAO/PAAO) et al.
Honorary Editors-in-Chief: Prof. Li-Xin Xie(Academician of Chinese Academy of
Engineering/Honorary President of Chinese Ophthalmological Society); Prof. Dennis Lam (President of APAO) and
Prof. Xiao-Xin Li (Ex-President of Chinese Ophthalmological Society).
Chief Editor: Prof. Xiu-Wen Hu (President of IJO Press).
Editors-in-Chief: Prof. Yan-Nian Hui (Ex-Director, Eye Institute of Chinese PLA) and
Prof. George Chiou (Founding chief editor of Journal of Ocular Pharmacology & Therapeutics).
Associate Editors-in-Chief include:
Prof. Ning-Li Wang (President Elect of APAO);
Prof. Ke Yao (President of Chinese Ophthalmological Society) ;
Prof.William Smiddy (Bascom Palmer Eye instituteUSA) ;
Prof.Joel Schuman (President of Association of University Professors of Ophthalmology,USA);
Prof.Yizhi Liu (Vice President of Chinese Ophtlalmology Society);
Prof.Yu-Sheng Wang (Director of Eye Institute of Chinese PLA);
Prof.Ling-Yun Cheng (Director of Ocular Pharmacology, Shiley Eye Center, USA).
IJO accepts contributions in English from all over the world. It includes mainly original articles and review articles,
both basic and clinical papers.
Instruction is Welcome Contribution is Welcome Citation is Welcome
Cooperation organization
International Council of Ophthalmology(ICO), PubMed, PMC, American Academy of Ophthalmology, Asia-Pacific, Thomson Reuters, The Charlesworth Group, Crossref,Scopus,Publons, DOAJ etc.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
